Lord, Abbett & Co
ADVM

Lord, Abbett & Co’s Adverum Biotechnologies ADVM Stock Holding History

Lord, Abbett & Co’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-8,015
Closed -$1.3M – 900
2015
Q2 		$1.3M Sell
8,015
-3,960
-33% -$1.34M ﹤0.01% 892
2015
Q1 		$4.85M Buy
11,975
+4,114
+52% +$1.74M 0.01% 746
2014
Q4 		$4.25M Sell
7,861
-2,347
-23% -$905K 0.01% 757
2014
Q3 		$3.49M Buy
+10,208
New +$3.04M 0.01% 800

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Lord, Abbett & Co's ADVM Position: Q3 2015 in Review

Lord, Abbett & Co sold out of Adverum Biotechnologies (ADVM) in Q3 2015, closing a stake of 8,015 shares — an estimated $1.3M sold.

Lord, Abbett & Co first reported a position in ADVM in Q3 2014 and held it in 4 quarters. The position peaked at $4.85M in Q1 2015. 92 funds tracked by Wall St. Rank hold ADVM as of Q3 2015.

  • Lord, Abbett & Co reported no remaining Adverum Biotechnologies position as of Q3 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 8,015 Adverum Biotechnologies shares in Q3 2015, an estimated $1.3M.
  • Lord, Abbett & Co first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 4 quarters.
  • Lord, Abbett & Co's Adverum Biotechnologies position peaked at $4.85M in Q1 2015.
  • 92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2015.

Based on Lord, Abbett & Co's 13F filing for Q3 2015, filed 16 Nov 2015.